A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions

CNS Drugs

Volumn 18, Issue 13, 2004, Pages 911-932

  Sullivan, Patrick W ^a   Valuck, Robert ^a   Saseen, Joseph ^a   MacFall, Holly M ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ATROPINE; CITALOPRAM; ESCITALOPRAM; FLUOXETINE; GENERIC DRUG; IBUPROFEN; LACTULOSE; LORAZEPAM; OMEPRAZOLE; PAROXETINE; PROCHLORPERAZINE; RANITIDINE; ROFECOXIB; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SILDENAFIL; TRAZODONE; VENLAFAXINE;

ABDOMINAL PAIN; AGITATION; ANALYTIC METHOD; ANOREXIA; ANXIETY DISORDER; ARTHRALGIA; ARTICLE; ASTHENIA; BAYES THEOREM; CARDIOVASCULAR DISEASE; COMPARATIVE STUDY; CONFUSION; CONSTIPATION; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COUGHING; DECISION MAKING; DEPRESSION; DIARRHEA; DIZZINESS; DRUG APPROVAL; DRUG EFFICACY; DRUG ERUPTION; DRUG INFORMATION; DRUG MARKETING; DYSMENORRHEA; DYSPEPSIA; EJACULATION DISORDER; FATIGUE; FEVER; FLATULENCE; FLU LIKE SYNDROME; FOOD AND DRUG ADMINISTRATION; HEADACHE; HEALTH STATUS; HEALTH SURVEY; HUMAN; HYPERTENSION; IMPOTENCE; INSOMNIA; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MANAGED CARE; MEASUREMENT; MENSTRUATION DISORDER; MENTAL DISEASE; MICTURITION DISORDER; MODEL; MONTE CARLO METHOD; MULTIVARIATE ANALYSIS; MUSCLE HYPERTONIA; MYALGIA; MYOPATHY; NAUSEA; NERVOUSNESS; PARAMETER; PARESTHESIA; PHARYNGITIS; PHOTOSENSITIVITY; PRESCRIPTION; PRIORITY JOURNAL; PROBABILITY; QUALITATIVE ANALYSIS; QUALITY OF LIFE; REGRESSION ANALYSIS; RHINITIS; SCORING SYSTEM; SENSITIVITY ANALYSIS; SEXUAL DYSFUNCTION; SINUSITIS; SOMNOLENCE; STIMULATION; SWEATING; TACHYCARDIA; TASTE DISORDER; TREMOR; UNITED STATES; UPPER RESPIRATORY TRACT INFECTION; UROGENITAL TRACT DISEASE; VAGINITIS; VISUAL DISORDER; VOMITING; WEIGHT REDUCTION; XEROSTOMIA; YAWNING;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CLINICAL TRIALS; COSTS AND COST ANALYSIS; DEPRESSION; HUMANS; MODELS, ECONOMIC; PROBABILITY; REVIEW LITERATURE; SENSITIVITY AND SPECIFICITY; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 10044266384     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200418130-00006     Document Type: Article

References (82)

1. Greenberg PE, Stiglin LE, Finkelstein SN, et al. The economic burden of depression in 1990. J Clin Psychiatry 1993 Nov; 54 (11): 405-18
2. Greenberg PE, Kessler RC, Birnbaum HG, et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry 2003 Dec, 64 (12)
3. Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 2000; 58 (1): 19-36
4. Song F, Freemantle N, Sheldon TA, et al. Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. BMJ 1993 Mar 13; 306 (6879): 683-7
5. Geddes JR, Freemantle N, Mason J, et al. SSRIs versus other antidepressants for depressive disorder. Cochrane Database Syst Rev 2000; (2): CD001851
6. Peretti S, Judge R, Hindmarch J. Safety and tolerability considerations: tricyclic antidepressants vs. selective serotonin reuptake inhibitors. Acta Psychiatr Scand Suppl 2000; 403: 17-25
7. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder. Am J Psychiatry 2000; 157 (4 Suppl.): 1-45
8. Fry RN, Avey SG, Sullivan SD. The Academy of Managed Care Pharmacy Format for Formulary Submissions: an evolving standard. A Foundation for Managed Care Pharmacy Task Force report. Value Health 2003 Sep; 6 (5): 505-21
9. Tai-Seale M, Croghan TW, Obenchain R. Determinants of antidepressant treatment compliance: implications for policy. Med Care Res Rev 2000; 57 (4): 491-512
10. Vaswani M, Linda FK, Ramesh S. Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27 (1): 85-102
11. Anderson IM, Tomenson BM. Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis. BMJ 1995; 310 (6992): 1433-8
12. Montgomery SA, Henry J, McDonald G, et al. Selective serotonin reuptake inhibitors: meta-analysis of discontinuation rates. Int Clin Psychopharmacol 1994; 9(1): 47-53
13. Barbui C, Hotopf M, Freemantle N, et al. Selective serotonin reuptake inhibitors versus tricyclic and heterocyclic antidepressants: comparison of drug adherence. Cochrane Database Syst Rev 2000; (4): CD002791
14. Panzarino PJ, Nash DB. Cost-effective treatment of depression with selective serotonin reuptake inhibitors. Am J Manag Care 2001; 7 (2): 173-84
15. Wilde MI, Whittington R. Paroxetine: a pharmacoeconomic evaluation of its use in depression. Pharmacoeconomics 1995; 8 (1): 62-81
16. Wilde MI, Benfield P. Fluoxetine: a pharmacoeconomic evaluation of its use in depression. Pharmacoeconomics 1998; 13 (5): 543-61
17. Davis R, Wilde MI. Sertraline: a pharmacoeconomic evaluation of its use in depression. Pharmacoeconomics 1996; 11 (4): 377-80
18. Burke W. Selective versus multi-transmitter antidepressants: are two mechanisms better than one? J Clin Psychiatry 2004; 65 Suppl. 4: 37-45
19. Olver JS, Burrows GD, Norman TR. Third-generation antidepressants: do they offer advantages over the SSRIs? CNS Drugs 2001; 15 (12): 941-54
20. Croom KF, Plosker GL. Escitalopram: a pharmacoeconomics review of its use in depression. Pharmacoeconomics 2003; 21 (16): 1185-209
21. Valuck R. Selective serotonin reuptake inhibitors: a class review. P&T 2004; 29 (4): 234-43
22. Rascati K, Godley P, Pham H. Evaluation of resources used to treat adverse events of selective serotonin reuptake inhibitor use. J Manag Care Pharm 2001; 7 (5): 402-6
23. Kroenke K, West SL, Swindle R, et al. Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial. JAMA 2001; 286 (23): 2947-55
24. Eli Lilly and Company. Prozac [package insert]. Indianapolis (IN), 2003 Nov
25. GlaxoSmithKline. Paxil [package insert]. Research Triangle Park (NC), 2004 Apr
26. Glaxo Smith Kline. Paxil CR [package insert]. Research Triangle Park (NC), 2004 Mar
27. Pfizer. Zoloft [package insert]. New York, 2003
28. Wyeth Pharmaceuticals. Effexor [package insert]. Philadelphia (PA), 2001 Mar
29. Wyeth Pharmaceuticals. Effexor XR [package insert]. Philadelphia (PA), 2003 Dec
30. Forest Pharmaceuticals. Citalopram [package insert]. St Louis (MO), 2004 Jan
31. Forest Pharmaceuticals. Escitalopram [package insert]. St Louis (MO), 2004 Dec
32. World Health Organization. International drug monitoring: the role of the hospital. Technical report series: No. 425. Geneva: World Health Organization, 1996
33. Bates DW, Boyle DL, Vander Vliet MB, et al. Relationship between medication errors and adverse drug events. J Gen Intern Med 1995; 10 (4): 199-205
34. Rodriguez-Monguio R, Otero M, Rovira J. Assessing the economic impact of adverse drug effects. Pharmacoeconomics 2003; 21 (9): 623-50
35. National Committee for Quality Assurance. The health plan employer data and information set (HEDIS®) 2003. Washington, DC: National Committee for Quality Assurance, 2003
36. Depression Guideline Panel. Clinical practice guideline, number 5. Depression in primary care: volume 2: treatment of major depression. AHCPR Publication No. 93-0551. Rockville (MD): US Department of Health and Human Services, Agency for Healthcare Policy and Research, 1993
37. Lenox-Smith A, Conway P, Knight C. Cost effectiveness of representatives of three classes of antidepressants used in major depression in the UK. Pharmacoeconomics 2004; 22 (5): 311-9
38. Boyer P, Danion JM, Bisserbe JC, et al. Clinical and economic comparison of sertraline and fluoxetine in the treatment of depression: a 6-month double-blind study in a primary-care setting in France. Pharmacoeconomics 1998; 13 (1 Pt 2): 157-69
39. Claxton AJ, Chawla AJ, Kennedy S. Absenteeism among employees treated for depression. J Occup Environ Med 1999; 41 (7): 605-11
40. Sclar DA, Skaer TL, Robison LM, et al. Economic appraisal of citalopram in the management of single-episode depression. J Clin Psychopharmacol 1999; 19 (5 Suppl. 1): 47S-54S
41. Simon GE, Fishman P. Cost implications of initial antidepressant selection in primary care. Pharmacoeconomics 1998; 13 (1 Pt 1): 61-70
42. François C, Toumi M, Aakhus AM, et al. A pharmacoeconomic evaluation of escitalopram, a new selective serotonin reuptake inhibitor. Eur J Health Econ 2003; 4 (1): 9-12
43. Valuck R. Treatment of depression with citalopram, fluoxetine, paroxetine, sertraline, and venlafaxine in managed care: part 1. Drug selection, dosing, and utilization. Drug Benefit Trends 2002; 14 (7): 23-30
44. Gold MR, Siegel JE, Russell LB, et al., editors. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996
45. Physician's desk reference. 57th ed. Montvale (NJ): Medical Economics, 2003
46. Fredman SJ, Fava M, Kienke AS, et al. Partial response, nonresponse, and relapse with selective serotonin reuptake inhibitors in major depression: a survey of current "next-step" practices. J Clin Psychiatry 2000; 61 (6): 403-8
47. Croghan TW, Lair TJ, Engelhart L, et al. Effect of antidepressant therapy on health care utilization and costs in primary care. Psychiatr Serv 1997; 48 (11): 1420-6
48. Bull SA, Hunkeler EM, Lee JY, et al. Discontinuing or switching selective serotonin-reuptake inhibitors. Ann Pharmacother 2002; 36 (4): 578-84
49. Hensley PL, Nurnberg HG. Formulary restriction of selective serotonin reuptake inhibitors for depression: potential pitfalls. Pharmacoeconomics 2001; 19 (10): 973-82
50. Brown WA, Harrison W. Are patients who are intolerant to one serotonin selective reuptake inhibitor intolerant to another? J Clin Psychiatry 1995; 56 (1): 30-4
51. Curkendall SM, Goehring EL, She D. Comparison of treatment cost for depression between fluoxetine, paroxetine, sertraline and venlafaxine using managed care claims data. Value Health 2002 May-Jun; 5 (3): 119
52. Crown WH, Finkelstein SN, Berndt ER, et al. The impact of treatment-resistant depression on healthcare utilization and costs. J Clin Psychiatry 2002; 63: 963-71
53. Masand PS. Tolerability and adherence issues in antidepressant therapy. Clin Ther Aug 2003; 25 (8): 2289-304
54. Drugstore.com. Pharmacy [online]. Available from URL: www.drugstore.com [Accessed 2004 May 14]
55. Department of Health and Human Services, Health Care Financing Administration. Medicare program: revisions to payment policies under the physician fee schedule for calendar year 2003. Fed Regist 2003; 68 (40): 9567
56. Baker CB, Woods SW. Cost of treatment failure for major depression: direct costs of continued treatment. Adm Policy Ment Health 2001; 28 (4): 263-77
57. McCombs JS, Nichol MB, Stimmel GL, et al. The cost of antidepressant drug therapy failure: a study of antidepressant use patterns in a Medicaid population. J Clin Psychiatry 1990; 51 Suppl.: 60-69; discussion 70-61
58. Agency for Healthcare Research and Quality, Center for Cost and Financing Studies. MEPS HC-052. 2000 medical conditions, June 2003 [online]. Available from URL: http:// www.meps.ahrq.gov/PUFFiles/H52/H52doc.htm [Accessed 2003 Nov 10]
59. Agency for Healthcare Research and Quality. Computing standard errors for MEPS estimates [online]. Available from URL: http://www.meps.AHRQ.gov [Accessed 2003 Sep]
60. Brooks RG, Jendteg S, Lindgren B, et al. EuroQol: health-related quality of life measurement. Results of the Swedish questionnaire exercise. Health Policy 1991; 18 (1): 37-48
61. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997; 35 (11): 1095-108
62. McDowell I, Newell C. Measuring health: a guide to rating scales and questionnaires. 2nd ed. New York: Oxford University Press, 1996
63. EuroQol [online]. Available from URL: http://ww-w.euroqol.org/download/ ref.pdf [Accessed 2003 Nov 11]
64. Health Care Financing Administration. The International classification of diseases, 9th rev., clinical modification: ICD-9-CM, 2nd ed. Washington (DC): US Government Printing Office, 1980
65. Elixhauser A, Andrews RM, Fox S. Clinical classifications for health policy research: discharge statistics by principal diagnosis and procedure. AHCPR Publication No. 93-0043. Rockville (MD): Agency for Health Policy and Research, 1993
66. Grootendorst P. Censoring in statistical models of health status: what happens when one can do better than '1'. Qual Life Res 2000; 9 (8): 911-4
67. Green WH. Econometric Analysis. 4th ed. Upper Saddle River (NJ): Prentice Hall, 2000
68. Maddala GS. Limited-dependent and qualitative variables in econometrics. Cambridge: Cambridge University Press, 1999
69. Powell J. Least absolute deviations estimation for the censored regression model. J Econometrics 1984; 25: 303-25
70. Austin PC. A comparison of methods for analyzing health-related quality-of-life measures. Value Health 2002 Jul-Aug; 5 (4): 329-37
71. Fryback DG, Stout NK, Rosenberg MA. An elementary introduction to Bayesian computing using WinBUGS. Int J Technol Assess Health Care 2001; 17 (1): 98-113
72. Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 2000; 17 (5): 479-500
73. Briggs AH, Goeree R, Blackhouse G, et al. Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease. Med Decis Making 2002 Jul-Aug; 22 (4): 290-308
74. Francois C, Sintonen H, Toumi M. Introduction of escitalopram, a new SSRI in Finland: comparison of cost-effectiveness between the other SSRIs and SNRI for the treatment of depression and estimation of the budgetary impact. J Med Econ 2002; 5: 91-107
75. François C, Henriksson F, Toumi M, et al. A Swedish pharmacoeconomic evaluation of escitalopram, a new SSRI: comparison of cost-effectiveness between escitalopram, citalopram, fluoxetine and venlafaxine [abstract]. Value Health 2002; 5 (3): 230
76. Wade A, McCrone P, Anderson I, et al. Cost-effectiveness of escitalopram, a new SSRI, in the treatment of major depressive disorder in the UK [abstract plus poster]. 1st Asia Pacific Conference for Pharmacoeconomic and Outcomes Research 2003 Sep 1-3, Kobe
77. Demyttenaere K, Rachidi S, Van Dijck P, et al. Cost-effectiveness of escitalopram compared to brand and generic SSRI (citalopram and fluoxetine), and venlafaxine in the treatment of depression in Belgium. Paris: Lundbeck A/S, 2003 (Data on file)
78. Montgomery SA, Fernandez JL, François C. Treatment of depression: escitalopram has similar efficacy but lower costs compared to venlafaxine XR [abstract no. PMH42]. Value Health 2003; 6 (3): 358
79. Naglie G, Krahn MD, Naimark D, et al. Primer on medical decision analysis. Part 3: estimating probabilities and utilities. Med Decis Making. 1997 Apr-Jun; 17 (2): 136-41
80. Prieto L, Sacristan JA. Problems and solutions in calculating quality-adjusted life years (QALYs). Health Qual Life Outcomes. 2003 Dec 19; 1 (1): 80
81. Gorman JM, Korotzer A, Su G. Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials. CNS Spectr 2002; 7 Suppl. 4: 40-4
82. Weinstein MC, Toy EL, Sandberg EA, et al. Modeling for health care and other policy decisions: uses, roles, and validity. Value Health 2001 Sep-Oct; 4 (5): 348-61